SCHEMBL4817675

SCHEMBL4817675

Fc1cccc(Cl)c1-c1c(Cl)nc2ncnn2c1NC1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
PDE2A O00408 4/20 0.39
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
FGFR1 P11362 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
CDK2 P24941 1/20 0.35
GSK3B P49841 1/20 0.35
OPRL1 P41146 2/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6867351 0.96 LMNA (0.38) LMNAPDE2AALDH1A1HPGDTSHR
SCHEMBL8386886 0.90 PDE2A (0.41) LMNAPDE2AKMT2AALDH1A1ADORA3
SCHEMBL7487750 0.87 MAPK1 (0.37) LMNAPDE2AKMT2AALDH1A1HPGD
SCHEMBL7490009 0.86 KMT2A (0.38) LMNAPDE2AKMT2AALDH1A1HPGD
SCHEMBL7496989 0.86 KMT2A (0.38) LMNAPDE2AKMT2AALDH1A1HPGD
SCHEMBL4816384 0.84 CDK2 (0.35) LMNAPDE2AKMT2AALDH1A1HPGD
SCHEMBL4818794 0.84 ADORA3 (0.43) LMNAPDE2AKMT2AALDH1A1ADORA3
SCHEMBL978477 0.84 KMT2A (0.36) PDE2AKMT2AALDH1A1HPGDTSHR
SCHEMBL7490647 0.82 EGLN2 (0.39) PDE2AKMT2AALDH1A1HPGDTSHR
SCHEMBL7958939 0.82 CDK2 (0.38) LMNAPDE2AKMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329663-B2 Substituted-triazolopyrimidines as anticancer agents WYETH (US) 2008-02-12 US claimed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US claimed
US-7329663-B2 Substituted-triazolopyrimidines as anticancer agents WYETH (US) 2008-02-12 US disclosed
EP-1307200-A2 SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS Wyeth (US) 2003-05-07 EP disclosed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US disclosed
WO-2002002563-A2 SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS WYETH (US) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents TUBB3, TUBA1C, TUBB1 LMNA 2723/4885PDE2A 3218/4885KMT2A 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.